Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants With Active Systemic Lupus Erythematosus

NCT04931563 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04931563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04931563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants With Active Systemic Lupus Erythematosus
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
September 13, 2021
Completion date
June 10, 2025
Enrollment
277 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

active systemic lupus erythematosus